Published in Ann Intern Med on February 01, 1972
Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine. J Virol (1976) 1.49
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
Cell-mediated immunity to Herpes simplex in humans: lymphocyte cytotoxicity measured by 51-Cr release from infected cells. Infect Immun (1975) 1.43
Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect. J Clin Invest (1980) 1.19
Specific in vitro antibody response to varicella zoster. Clin Exp Immunol (1981) 1.15
Cell-mediated immunity to Varicella-Zoster antigen in acute Herpes zoster (shingles). Clin Exp Immunol (1973) 1.14
Defective in vitro antibody production to Varicella zoster and other virus antigens in patients with Hodgkin's disease. Clin Exp Immunol (1983) 1.08
Immunodeficiency states. Proc R Soc Med (1974) 1.07
Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ (2012) 0.98
Herpesviruses. J Clin Pathol (1979) 0.89
Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and Outcomes. Autoimmune Dis (2010) 0.85
Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis. Br J Cancer (1982) 0.78
Neurological manifestations in a patient with visceral leishmaniasis. Postgrad Med J (1998) 0.76
Zoster and Hodgkin's disease. Br Med J (1972) 0.75
Rapid identification of virus infections. Br Med J (1976) 0.75
The significance of the determination of lymphocytes with clinical manifestation of ophthalmic zoster sine herpete. Clin Ophthalmol (2010) 0.75
Herpes zoster. West J Med (1978) 0.75
Increased luminol-enhanced chemiluminescence of blood monocytes and granulocytes in Hodgkin's disease. Clin Exp Immunol (1991) 0.75
The effect of quadruple chemotherapy on the peripheral blood lymphocyte populations in Hodgkin's disease. Br J Clin Pharmacol (1977) 0.75
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med (1989) 2.46
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 2.32
Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. J Infect Dis (1982) 2.29
Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest (1985) 2.28
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Interferon inducers in vitro: difference in sensitivity to inhbitiros of RNA and protein synthesis. Science (1968) 2.16
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology (1988) 2.14
Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol (1975) 2.09
Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med (1977) 2.09
Measles in adults. An unforeseen consequence of immunization? JAMA (1976) 2.08
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med (1978) 2.04
Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology (1968) 1.96
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med (1977) 1.93
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Induction of circulating interferon by synthetic anionic polymers of known composition. Nature (1967) 1.92
Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp Biol Med (1967) 1.85
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis (1995) 1.77
The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. J Clin Invest (1971) 1.75
PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. Cell Immunol (1971) 1.75
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol (1997) 1.74
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
A useful quantitative semimicromethod for viral plaque assay. Proc Soc Exp Biol Med (1973) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol (1985) 1.73
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. J Clin Microbiol (1995) 1.69
An artificial intelligence program to advise physicians regarding antimicrobial therapy. Comput Biomed Res (1973) 1.69
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 1.68
Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infect Immun (1976) 1.67
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol (1977) 1.64
Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas. Cancer (1973) 1.60
Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol (1984) 1.60
Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J Immunol (1974) 1.60
Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med (1984) 1.58
Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. J Infect Dis (1971) 1.56
Current concepts of interferon and interferon induction. Annu Rev Med (1970) 1.53
Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys (1991) 1.53
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 1.52
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology (1981) 1.49
Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen. J Immunol (1975) 1.49
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Virology (1989) 1.49
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 1.48
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol (1995) 1.48
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
Hereditary occurrence of cystic disease of the renal medulla. N Engl J Med (1966) 1.46
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr (1994) 1.44
Diagnosis of cytomegalovirus pneumonia in compromised hosts. Am J Med (1976) 1.44
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med (1978) 1.44
Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cell Immunol (1978) 1.43
Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature (1969) 1.43
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis (1991) 1.43
Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA (1982) 1.42
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother (1997) 1.42
Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med (1978) 1.42
Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum (1981) 1.41
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. J Infect Dis (1974) 1.40
Resistance to virus challenge in mice infected with protozoa or bacteria. Proc Soc Exp Biol Med (1969) 1.40
Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Ann Intern Med (1980) 1.39
In vitro production and cellular origin of murine type II interferon. Immunology (1979) 1.39
Toxicity of vidarabine. JAMA (1979) 1.39
Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Lab Invest (1984) 1.38
Septicemia with Pasteurella pseudotuberculosis and liver disease. Arch Intern Med (1971) 1.37
The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer (1995) 1.37
Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis (1981) 1.36
Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy. Cancer (1976) 1.35
Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. Proc Natl Acad Sci U S A (1978) 1.35
Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia. N Engl J Med (1970) 1.34